Pharmacodynamics of Intra-arterial vs Intravenous Gemcitabine in Locally Advanced Pancreatic Cancer: Results of a Phase III Randomized Clinical Trial Pharmacodynamics of Intra-arterial vs Intravenous Gemcitabine in Locally Advanced Pancreatic Cancer: Results of a Phase III Randomized Clinical Trial

RenovoRx today announced its financial results for the third quarter ended September 30, 2026 and provided shareholders with a business update highlighting continued commercial momentum and clinical progress.

RenovoRx today announced that it will release third quarter 2026 financial results and business highlights after market close on Thursday, November 5, 2026, and host a conference call and webcast at 4:30 p.m. ET.